Septerna (SEPN) Cash from Financing Activities (2024 - 2026)
Septerna's quarterly Cash from Financing Activities came in at $333000.0 in Q1 2026, up 404.55% year-on-year from $66000.0 in Q1 2025, and down 67.38% quarter-over-quarter from $1.0 million in Q4 2025.
Septerna has reported Cash from Financing Activities for 3 years, with the latest figure at $333000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 404.55% year-over-year to $333000.0; the trailing twelve-month figure through Mar 2026 stood at $2.0 million (down 99.35% YoY), and the FY2025 full-year result was $1.7 million, down 99.55% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $333000.0, down from $1.0 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $304.2 million in Q4 2024, with the low at -$1.3 million in Q3 2024.
- Average Cash from Financing Activities over 3 years is $43.6 million, with a median of $333000.0 recorded in 2026.
- Year-over-year, Cash from Financing Activities sank 99.66% in 2025 and jumped 404.55% in 2026.
- Tracing SEPN's Cash from Financing Activities over 3 years: stood at $304.2 million in 2024, then slumped by 99.66% to $1.0 million in 2025, then slumped by 67.38% to $333000.0 in 2026.
- The last three Cash from Financing Activities figures came in at $333000.0 (Q1 2026), $1.0 million (Q4 2025), and $263000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Septerna | 1.34 Bn | 1.34 Bn | - | 333,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 333,000.00 |
| Mar 31, 2026 | 333,000.00 |
| Dec 31, 2025 | 1.02 Mn |
| Dec 31, 2025 | 1.02 Mn |
| Sep 30, 2025 | 263,000.00 |
| Sep 30, 2025 | 263,000.00 |
| Jun 30, 2025 | 339,000.00 |
| Jun 30, 2025 | 339,000.00 |
| Mar 31, 2025 | 66,000.00 |
| Mar 31, 2025 | 66,000.00 |
| Dec 31, 2024 | 304.15 Mn |
| Dec 31, 2024 | 304.15 Mn |
| Sep 30, 2024 | -1.32 Mn |
| Sep 30, 2024 | -1.32 Mn |